Epigenetic regulation of vascular smooth muscle cell function in atherosclerosis

Current Atherosclerosis Reports

Volumn 15, Issue 5, 2013, Pages

  Findeisen, Hannes M ^a   Kahles, Florian K ^a   Bruemmer, Dennis ^b  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Atherosclerosis; Chromatin remodeling; DNA methylation; Epigenetic; Histone modification; SMC; Smooth muscle cells

Indexed keywords

ARTERY CALCIFICATION; ARTICLE; ATHEROSCLEROSIS; CELL DIFFERENTIATION; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; DIABETES MELLITUS; DISEASE ASSOCIATION; DNA METHYLATION; DNA MODIFICATION; EPIGENETICS; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; GENETIC REGULATION; HISTONE ACETYLATION; HUMAN; HYPERTENSION; INFLAMMATION; NONHUMAN; PATHOGENESIS; SIGNAL TRANSDUCTION; VASCULAR REMODELING; VASCULAR SMOOTH MUSCLE CELL; CHROMATIN ASSEMBLY AND DISASSEMBLY; CYTOLOGY; GENETIC EPIGENESIS; GENETICS; METABOLISM; PROTEIN PROCESSING; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

HISTONE;

ATHEROSCLEROSIS; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; HISTONES; HUMANS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PROTEIN PROCESSING, POST-TRANSLATIONAL; CELL PROLIFERATION;

MLCS; MLOWN;

EID: 84924924143     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-013-0319-7     Document Type: Article

References (83)

1. Kouzarides T. Chromatin modifications and their function. Cell. 2007;128(4):693-705.
2. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150(1):12-27.
3. Tan M, Luo H, Lee S, Jin F, Yang JS, et al. Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification. Cell. 2011;146(6):1016-28.
4. Baylin SB, Jones PA. A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer. 2011;11(10):726-34.
5. Robertson KD. DNA methylation and human disease. Nat Rev Genet. 2005;6(8):597-610.
6. Suzuki MM, Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet. 2008;9(6):465-76.
7. Doi A, Park IH, Wen B, Murakami P, Aryee MJ, et al. Differential methylation of tissue-and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet. 2009;41(12):1350-3.
8. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002;16(1):6-21.
9. Ito S, Shen L, Dai Q, Wu SC, Collins LB, et al. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science. 2011;333(6047):1300-3.
10. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009;324(5929):930-5.
11. Jeppesen P, Turner BM. The inactive x chromosome in female mammals is distinguished by a lack of histone h4 acetylation, a cytogenetic marker for gene expression. Cell. 1993;74(2):281-9.
12. Braunstein M, Rose AB, Holmes SG, Allis CD, Broach JR. Transcriptional silencing in yeast is associated with reduced nucleosome acetylation. Genes Dev. 1993;7(4):592-604.
13. Lachner M, O'Carroll D, Rea S, Mechtler K, Jenuwein T. Methylation of histone h3 lysine 9 creates a binding site for hp1 proteins. Nature. 2001;410(6824):116-20.
14. Li B, Carey M, Workman JL. The role of chromatin during transcription. Cell. 2007;128(4):707-19.
15. Jenuwein T, Allis CD. Translating the histone code. Science. 2001;293(5532):1074-80.
16. Euskirchen G, Auerbach RK, Snyder M. SWI/SNF chromatinremodeling factors: multiscale analyses and diverse functions. J Biol Chem. 2012;287(37):30897-905.
17. Cheung P, Lau P. Epigenetic regulation by histone methylation and histone variants. Mol Endocrinol. 2005;19(3):563-73.
18. Lorenzen JM, Martino F, Thum T. Epigenetic modifications in cardiovascular disease. Basic Res Cardiol. 2012;107(2):245.
19. Alkemade FE, van Vliet P, Henneman P, van Dijk KW, Hierck BP, et al. Prenatal exposure to apoE deficiency and postnatal hypercholesterolemia are associated with altered cell-specific lysine methyltransferase and histone methylation patterns in the vasculature. Am J Pathol. 2010;176(2):542-8.
20. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473(7347):317-25.
21. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32(9):2045-51.
22. Doran AC, Meller N, McNamara CA. Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc Biol. 2008;28(5):812-9.
23. Lacolley P, Regnault V, Nicoletti A, Li Z, Michel JB. The vascular smooth muscle cell in arterial pathology: a cell that can take on multiple roles. Cardiovasc Res. 2012;95(2):194-204.
24. Alexander MR, Owens GK. Epigenetic control of smooth muscle cell differentiation and phenotypic switching in vascular development and disease. Annu Rev Physiol. 2012;74:13-40.
25. Spin JM, Maegdefessel L, Tsao PS. Vascular smooth muscle cell phenotypic plasticity: focus on chromatin remodelling. Cardiovasc Res. 2012;95(2):147-55.
26. Mack CP, Thompson MM, Lawrenz-Smith S, Owens GK. Smooth muscle alpha-actin CArG elements coordinate formation of a smooth muscle cell-selective, serum response factor-containing activation complex. Circ Res. 2000;86(2):221-32.
27. McDonald OG, Wamhoff BR, Hoofnagle MH, Owens GK. Control of SRF binding to CArG box chromatin regulates smooth muscle gene expression in vivo. J Clin Invest. 2006;116(1):36-48.
28. Manabe I, Owens GK. Recruitment of serum response factor and hyperacetylation of histones at smooth muscle-specific regulatory regions during differentiation of a novel P19-derived in vitro smooth muscle differentiation system. Circ Res. 2001;88(11):1127-34.
29. Cao D, Wang Z, Zhang CL, Oh J, Xing W, et al. Modulation of smooth muscle gene expression by association of histone acetyltransferases and deacetylases with myocardin. Mol Cell Biol. 2005;25(1):364-76.
30. Qiu P, Li L. Histone acetylation and recruitment of serum responsive factor and CREB-binding protein onto SM22 promoter during SM22 gene expression. Circ Res. 2002;90(8):858-65.
31. Spin JM, Quertermous T, Tsao PS. Chromatin remodeling pathways in smooth muscle cell differentiation, and evidence for an integral role for p300. PLoS One. 2010;5(12):e14301.
32. Yoshida T, Gan Q, Shang Y, Owens GK. Platelet-derived growth factor-BB represses smooth muscle cell marker genes via changes in binding of MKL factors and histone deacetylases to their promoters. Am J Physiol Cell Physiol. 2007;292(2):C886-95.
33. Yoshida T, Gan Q, Owens GK. Kruppel-like factor 4, Elk-1, and histone deacetylases cooperatively suppress smooth muscle cell differentiation markers in response to oxidized phospholipids. Am J Physiol Cell Physiol. 2008;295(5):C1175-82.
34. Salmon M, Gomez D, Greene E, Shankman L, Owens GK. Cooperative binding of KLF4, pELK-1, and HDAC2 to a G/C repressor element in the SM22α promoter mediates transcriptional silencing during SMC phenotypic switching in vivo. Circ Res. 2012;111(6):685-96.
35. Gan Q, Thiébaud P, Thézé N, Jin L, Xu G, et al. WD repeatcontaining protein 5, a ubiquitously expressed histone methyltransferase adaptor protein, regulates smooth muscle cell-selective gene activation through interaction with pituitary homeobox 2. J Biol Chem. 2011;286(24):21853-64.
36. Lockman K, Taylor JM, Mack CP. The histone demethylase, Jmjd1a, interacts with the myocardin factors to regulate SMC differentiation marker gene expression. Circ Res. 2007;101(12):e115-23.
37. Zhang QJ, Goddard M, Shanahan C, Shapiro L, Bennett M. Differential gene expression in vascular smooth muscle cells in primary atherosclerosis and in stent stenosis in humans. Arterioscler Thromb Vasc Biol. 2002;22(12):2030-6.
38. Zhou J, Zhang M, Fang H, El-Mounayri O, Rodenberg JM, et al. The SWI/SNF chromatin remodeling complex regulates myocardin-induced smooth muscle-specific gene expression. Arterioscler Thromb Vasc Biol. 2009;29(6):921-8.
39. Zhang M, Chen M, Kim JR, Zhou J, Jones RE, et al. SWI/SNF complexes containing Brahma or Brahma-related gene 1 play distinct roles in smooth muscle development. Mol Cell Biol. 2011;31(13):2618-31.
40. Hiltunen MO, Turunen MP, Häkkinen TP, Rutanen J, Hedman M, et al. DNA hypomethylation and methyltransferase expression in atherosclerotic lesions. Vasc Med. 2002;7(1):5-11.
41. Laukkanen MO, Mannermaa S, Hiltunen MO, Aittomaki S, Airenne K, et al. Local hypomethylation in atherosclerosis found in rabbit ec-sod gene. Arterioscler Thromb Vasc Biol. 1999;19:2171-8.
42. Zhang H, Gu S, Al-Sabeq B, Wang S, He J, et al. Origin-specific epigenetic program correlates with vascular bed-specific differences in Rgs5 expression. FASEB J. 2012;26(1):181-91.
43. Ying AK, Hassanain HH, Roos CM, Smiraglia DJ, Issa JJ, et al. Methylation of the estrogen receptor-alpha gene promoter is selectively increased in proliferating human aortic smooth muscle cells. Cardiovasc Res. 2000;46(1):172-9.
44. Dzau VJ, Braun-Dullaeus RC, Sedding DG. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med. 2002;8(11):1249-56.
45. Zhou B, Margariti A, Zeng L, Xu Q. Role of histone deacetylases in vascular cell homeostasis and arteriosclerosis. Cardiovasc Res. 2011;90(3):413-20.
46. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007;26(37):5541-52.
47. Sambucetti LC, Fischer DD, Zabludoff S, Kwon PO, Chamberlin H, et al. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem. 1999;274(49):34940-7.
48. Findeisen HM, Gizard F, Zhao Y, Qing H, Heywood EB, et al. Epigenetic regulation of vascular smooth muscle cell proliferation and neointima formation by histone deacetylase inhibition. Arterioscler Thromb Vasc Biol. 2011;31(4):851-60.
49. Okamoto H, Fujioka Y, Takahashi A, Takahashi T, Taniguchi T, et al. Trichostatin A, an inhibitor of histone deacetylase, inhibits smooth muscle cell proliferation via induction of p21(WAF1). J Atheroscler Thromb. 2006;13(4):183-91.
50. Kee HJ, Kwon JS, Shin S, Ahn Y, Jeong MH, et al. Trichostatin A prevents neointimal hyperplasia via activation of Krüppel like factor 4. Vascul Pharmacol. 2011;55(5-6):127-34.
51. Mathew OP, Ranganna K, Yatsu FM. Butyrate, an HDAC inhibitor, stimulates interplay between different posttranslational modifications of histone H3 and differently alters G1-specific cell cycle proteins in vascular smooth muscle cells. Biomed Pharmacother. 2010;64(10):733-40.
52. Zhou B, Margariti A, Zeng L, Habi O, Xiao Q, et al. Splicing of histone deacetylase 7 modulates smooth muscle cell proliferation and neointima formation through nuclear β-catenin translocation. Arterioscler Thromb Vasc Biol. 2011;31(11):2676-84.
53. Li L, Zhang HN, Chen HZ, Gao P, Zhu LH, et al. SIRT1 acts as a modulator of neointima formation following vascular injury in mice. Circ Res. 2011;108(10):1180-9.
54. Yan ZQ, Yao QP, Zhang ML, Qi YX, Guo ZY, et al. Histone deacetylases modulate vascular smooth muscle cell migration induced by cyclic mechanical strain. J Biomech. 2009;42(7):945-8.
55. Azahri NS, Di Bartolo BA, Khachigian LM, Kavurma MM. Sp1, acetylated histone-3 and p300 regulate TRAIL transcription: Mechanisms of PDGF-BB-mediated VSMC proliferation and migration. J Cell Biochem. 2012;113(8):2597-606.
56. Orr AW, Hastings NE, Blackman BR, Wamhoff BR. Complex regulation and function of the inflammatory smooth muscle cell phenotype in atherosclerosis. J Vasc Res. 2010;47(2):168-80.
57. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94(6):2493-503.
58. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002;90(3):251-62.
59. Pons D, de Vries FR, van den Elsen PJ, Heijmans BT, Quax PH, et al. Epigenetic histone acetylation modifiers in vascular remodelling: new targets for therapy in cardiovascular disease. Eur Heart J. 2009;30(3):266-77.
60. Chernov AV, Strongin AY. Epigenetic regulation of matrix metalloproteinases and their collagen substrates in cancer. Biomol Concepts. 2011;2(3):135-47.
61. Vinh A, Gaspari TA, Liu HB, Dousha LF, Widdop RE, et al. A novel histone deacetylase inhibitor reduces abdominal aortic aneurysm formation in angiotensin II-infused apolipoprotein Edeficient mice. J Vasc Res. 2008;45(2):143-52.
62. Gomez D, Coyet A, Ollivier V, Jeunemaitre X, Jondeau G, Michel JB, et al. Epigenetic control of vascular smooth muscle cells in Marfan and non-Marfan thoracic aortic aneurysms. Cardiovasc Res. 2011;89(2):446-56.
63. Chen KC, Wang YS, Hu CY, Chang WC, Liao YC, et al. OxLDL up-regulates microRNA-29b, leading to epigenetic modifications of MMP-2/MMP-9 genes: a novel mechanism for cardiovascular diseases. FASEB J. 2011;25(5):1718-28.
64. Chen KC, Liao YC, Hsieh IC, Wang YS, Hu CY, et al. OxLDL causes both epigenetic modification and signaling regulation on the microRNA-29b gene: novel mechanisms for cardiovascular diseases. J Mol Cell Cardiol. 2012;52(3):587-95.
65. Bennett MR. Apoptosis of vascular smooth muscle cells in vascular remodelling and atherosclerotic plaque rupture. Cardiovasc Res. 1999;41(2):361-8.
66. Kavurma MM, Figg N, Bennett MR, Mercer J, Khachigian LM, et al. Oxidative stress regulates IGF1R expression in vascular smooth-muscle cells via p53 and HDAC recruitment. Biochem J. 2007;407(1):79-87.
67. Shao JS, Cai J, Towler DA. Molecular mechanisms of vascular calcification: lessons learned from the aorta. Arterioscler Thromb Vasc Biol. 2006;26(7):1423-30.
68. Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res. 2011;109(6):697-711.
69. Iyemere VP, Proudfoot D, Weissberg PL, Shanahan CM. Vascular smooth muscle cell phenotypic plasticity and the regulation of vascular calcification. J Intern Med. 2006;260(3):192-210.
70. Takemura A, Iijima K, Ota H, Son BK, Ito Y, et al. Sirtuin 1 retards hyperphosphatemia-induced calcification of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2011;31(9):2054-62.
71. Montes de Oca A, Madueño JA, Martinez-Moreno JM, Guerrero F, Muñoz-Castañeda J, et al. High-phosphate-induced calcification is related to SM22α promoter methylation in vascular smooth muscle cells. J Bone Miner Res. 2010;25(9):1996-2005.
72. Indolfi C, Torella D, Cavuto L, Davalli AM, Coppola C, et al. Effects of balloon injury on neointimal hyperplasia in streptozotocin-induced diabetes and in hyperinsulinemic nondiabetic pancreatic islettransplanted rats. Circulation. 2001;103(24):2980-6.
73. Golovchenko I, Goalstone ML, Watson P, Brownlee M, Draznin B. Hyperinsulinemia enhances transcriptional activity of nuclear factor-kappaB induced by angiotensin II, hyperglycemia, and advanced glycosylation end products in vascular smooth muscle cells. Circ Res. 2000;87(9):746-52.
74. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643-53.
75. Reddy MA, Natarajan R. Epigenetic mechanisms in diabetic vascular complications. Cardiovasc Res. 2011;90(3):421-9.
76. Villeneuve LM, Reddy MA, Lanting LL, Wang M, Meng L, et al. Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. Proc Natl Acad Sci U S A. 2008;105(26):9047-52.
77. Villeneuve LM, Kato M, Reddy MA, Wang M, Lanting L, et al. Enhanced levels of microRNA-125b in vascular smooth muscle cells of diabetic db/db mice lead to increased inflammatory gene expression by targeting the histone methyltransferase Suv39h 1. Diabetes. 2010;59(11):2904-15.
78. Reddy MA, Sahar S, Villeneuve LM, Lanting L, Natarajan R. Role of Src tyrosine kinase in the atherogenic effects of the 12/15-lipoxygenase pathway in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2009;29(3):387-93.
79. Sahar S, Reddy MA, Wong C, Meng L, Wang M, et al. Cooperation of SRC-1 and p300 with NF-kappaB and CREB in angiotensin II-induced IL-6 expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2007;27(7):1528-34.
80. Xu X, Ha CH, Wong C, Wang W, Hausser A, et al. Angiotensin II stimulates protein kinase D-dependent histone deacetylase 5 phosphorylation and nuclear export leading to vascular smooth muscle cell hypertrophy. Arterioscler Thromb Vasc Biol. 2007;27(11):2355-62.
81. Li H, Li W, Gupta AK, Mohler PJ, Anderson ME, et al. Calmodulin kinase II is required for angiotensin II-mediated vascular smooth muscle hypertrophy. Am J Physiol Heart Circ Physiol. 2010;298(2):H688-98.
82. Usui T, Okada M, Mizuno W, Oda M, Ide N, et al. HDAC4 mediates development of hypertension via vascular inflammation in spontaneous hypertensive rats. Am J Physiol Heart Circ Physiol. 2012;302(9):H1894-904.
83. Choi JH, Nam KH, Kim J, Baek MW, Park JE, et al. Trichostatin A exacerbates atherosclerosis in low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2005;25(11):2404-9.